

Claim Amendments

Claim 1 (cancelled)

Claims 2 and 3 (previously cancelled)

Claim 4 (cancelled)

Claim 5 (amended)

-- 5. (Amended) A pharmaceutical composition comprising a core in the form of a beadlet and an enteric coating for said core, said core comprising about 80% to about 100% by weight of an acid labile medicament which is 2',3'-dideoxyinosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, sodium alginate and partially pregelatinized corn starch, said composition being devoid of a protective coat or subcoat between the core and the enteric coating. --

Claim 6 (cancelled)

Claims 7 to 24 (original)

7. The pharmaceutical composition of Claim 5 wherein the weight ratio of enteric coating to core is between about 0.05:1 to about 0.6:1.

8. The pharmaceutical composition of Claim 5 wherein said enteric coating comprises a polymer and a plasticizer.

9. The pharmaceutical composition of Claim 8 wherein said polymer is selected from the group consisting of hydroxypropylmethylcellulose phthalate, polyvinyl acetate phthalate and cellulose acetate phthalate.

10. The pharmaceutical composition of Claim 8 wherein said polymer comprises a methacrylic acid copolymer.

11. The pharmaceutical composition of Claim 10 wherein said enteric coating includes the methacrylic acid copolymer in an amount within the range of from about 5 to about 30% of the total composition weight, and said plasticizer in an amount within the range from about 0.5 to about 6% of the total composition weight.

12. The pharmaceutical composition of Claim 10 wherein said methacrylic acid copolymer is methacrylic acid copolymer.

13. The pharmaceutical composition of Claim 8 wherein said plasticizer is triethyl citrate, triacetin, tributyl sebecate, or polyethylene glycol.

14. The pharmaceutical composition of Claim 8 wherein said plasticizer is diethyl phthalate.

15. The pharmaceutical composition of Claim 8 wherein said enteric coating includes methacrylic acid copolymer and diethyl phthalate.

16. The pharmaceutical composition of Claim 5, further comprising an anti-adherent coating disposed on the exterior of said enteric coating.

17. The pharmaceutical composition of Claim 16 wherein said anti-adherent coating is a hydrophobic material.

18. The pharmaceutical composition of Claim 17 wherein the anti-adherent coating is magnesium stearate or fumed silica.

19. The pharmaceutical composition of Claim 18 wherein the anti-adherent coating is talc.

20. The pharmaceutical composition of Claim 16 wherein said anti-adherent is present in an amount within the range from about 0.1% to about 4.0% of the total composition weight.

21. The pharmaceutical composition of Claim 5 wherein said disintegrant is cross-linked sodium carboxymethylcellulose, corn starch, or cross linked polyvinylpyrrolidone.

22. The pharmaceutical composition of Claim 5 wherein said disintegrant is sodium starch glycolate.

23. The pharmaceutical composition of Claim 5 wherein said binder is alkaline.

24. The pharmaceutical composition of Claim 23 wherein said binder is sodium carboxymethylcellulose.

Claims 25 and 26 (previously cancelled)

Claim 27 (previously amended)

-- 27. (Amended) The pharmaceutical composition of Claim 5 wherein said core comprises about 95% by weight 2',3'-dideoxyinosine, about 1% by weight sodium carboxymethylcellulose and about 4% by weight sodium starch glycolate. --

Claim 28 (previously amended)

-- 28. (Amended) The pharmaceutical composition of Claim 5 wherein said composition is encapsulated in a capsule for oral administration. --

Claims 29 to 31 (original)

29. The pharmaceutical composition of Claim 28 wherein said capsule is filled with said composition in an amount equivalent to attain a dosage of ddl required for twice daily administration.

30. The pharmaceutical composition of Claim 28 wherein said capsule is filled with said composition in an amount equivalent to attain a dosage of ddl required for once daily administration.

31. A pharmaceutical composition comprising:

a) a dissolvable capsule; and

b) the pharmaceutical composition of Claims 5, 16, or 27 which is encapsulated within said dissolvable capsule.

Claims 32 to 53 (withdrawn)